Profile data is unavailable for this security.
About the company
Tanvex BioPharma, Inc. is a Cayman Islands-based contract development and manufacturing organization (CDMO) for biologics and a biosimilars products company. The Company specializes in research, product development, manufacture, and commercialization of biologic and biosimilar drugs. It has expertise in all areas, such as strain and cell-line development in both microbial and mammalian systems, cell culture, protein purification, process scale-up, drug substance and product manufacturing, and warehousing, sales and distribution. The Company's CDMO services operate under the name Bora Biologics. The Company’s product pipeline includes Neupogen (TX-01), Herceptin (TX-05), Neulasta (TX-04), Avastin (TX-16), Perjeta (TX-52), and others. It deploys a range of Current Good Manufacturing Practice (cGMP) biologics manufacturing capabilities.
- Revenue in TWD (TTM)224.83m
- Net income in TWD-1.36bn
- Incorporated2013
- Employees133.00
- LocationTanvex BioPharma IncGrand PavilionHibiscus Way, 802 West Bay RoadP.O. Box 31119GRAND CAYMAN KY1-1205Cayman IslandsCYM
- Websitehttps://www.tanvex.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tanvex Biopharma Inc | 224.83m | -1.36bn | 12.74bn | 133.00 | -- | 2.12 | -- | 56.69 | -6.26 | -6.26 | 1.02 | 22.66 | 0.0403 | 1.59 | 3.61 | 1,690,436.00 | -24.32 | -47.80 | -26.85 | -52.28 | -86.98 | 42.14 | -603.94 | -7,091.22 | 2.39 | -15.08 | 0.2049 | -- | -43.53 | -- | 35.35 | -- | 3.43 | -- |
| Holder | Shares | % Held |
|---|---|---|
| SSgA Funds Management, Inc.as of 08 Jan 2026 | 79.00k | 0.03% |
